WO1998041540A1 - Ligands radiomarques du recepteur de la somatostatine pour le diagnostic et la theraphie - Google Patents

Ligands radiomarques du recepteur de la somatostatine pour le diagnostic et la theraphie Download PDF

Info

Publication number
WO1998041540A1
WO1998041540A1 PCT/AT1998/000065 AT9800065W WO9841540A1 WO 1998041540 A1 WO1998041540 A1 WO 1998041540A1 AT 9800065 W AT9800065 W AT 9800065W WO 9841540 A1 WO9841540 A1 WO 9841540A1
Authority
WO
WIPO (PCT)
Prior art keywords
carrier substance
diagnosis
peptide
compound
metal
Prior art date
Application number
PCT/AT1998/000065
Other languages
German (de)
English (en)
Inventor
Irene Virgolini
Peter Smith-Jones
Peter Angelberger
Original Assignee
Nycomed Imaging As
Irene Virgolini
Smith Jones Peter
Peter Angelberger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging As, Irene Virgolini, Smith Jones Peter, Peter Angelberger filed Critical Nycomed Imaging As
Priority to CA002284581A priority Critical patent/CA2284581A1/fr
Priority to AU66021/98A priority patent/AU6602198A/en
Priority to EP98907750A priority patent/EP0975670A1/fr
Priority to JP53994098A priority patent/JP2001515494A/ja
Publication of WO1998041540A1 publication Critical patent/WO1998041540A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

  • the invention relates to a carrier substance for metal compounds for diagnosis and / or destruction of tumor tissue, which selectively binds the substance to the somatostatin-binding surface receptors of the affected cells, a macrocyclic chelating agent being bound to a somatostatin 14 agonist
  • peptides such as (D) Phe-Cys-Tyr- (D) Trp-Lys-Thr-Cys-Thr (ol) (Tyr 3 -Octreotide, 2) and m In-DTPA- (D) Phe-Cys-Phe- (D) Trp-Lys-Thr-Cys-Thr (ol) ((DTPA) - (D) Phe 1 -Octreotide, 3) used to localize malignancies such as neuroendocrine tumors, breast cancer and lymphomas
  • Radioiodinated NDP vasoactive intestinal peptide, 4
  • This radioligand ie 123 I-VIP
  • ie 123 I-VIP not only binds to neuroendocrine tumors with high affinity, but also especially on a variety of adenocarcinomas that cannot be visualized with 111 In-DTPA- (D) Phe 1 octreotide.
  • somatostatin receptors So far, five different human somatostatin receptors (hSSTRl-5) and two different VIP receptors have been characterized and cloned. Using transfected peptide receptors, the SSTR3 subtype has been found to be the most widely used among somatostatin receptors Binding site for somatostatin in the tumor tissue is. It was also shown that VIP binds to SSTR3 and that the binding of somatostatin and VIP is cross-competitive to primary tumor cells.
  • the binding of peptides to tumor receptors can not only be used to diagnose the location of tumors and their metastases.
  • the 111 In-DTPA (D) Phe 1 octreotide used for diagnostic purposes has already been used in high doses as a receptor ligand for targeted radiotherapy.
  • EP 0 714 911 A2 shows that a conjugate of an octapeptide with the common name octreotide and a macrocyclic chelator 1,4,7,10-tetraazacyclododecane-N, N ', N ", N"' -tetraacetic acid (DOTA ), a radionuclide can complex so that it can be used in vivo for the therapy of tumors.
  • This patent is limited to the therapeutic use of said substance.
  • Octreotide only binds to some of the high affinity somatostatin 14 subtype receptors that have now been found.
  • 111 In-DTPA- (D) Phe 1 -octreotide is also taken up in kidney, liver and spleen, which leads to an unnecessarily high radiation exposure of these organs.
  • the invention is based on the object of creating a carrier molecule of the type mentioned at the outset which has the broadest possible somatostatin 14 receptor subtype recognition profile (hSSTR2-5) and has little stress on healthy body tissue and thus has better biodistribution.
  • the effect would be a higher dose in the tumor tissue and a lower radiation exposure of the healthy tissue, especially of the spleen and kidney.
  • the invention solves this problem in that as a somatostatin 14 agonist
  • (D) ßNal-Cys-Tyr- (D) Trp-Lys-Val-Cys-Thr-NHR 1 (I) is bound to the macrocyclic chelating agent via its C or N terminus (example 1).
  • This octapeptide is known under the name "lanreotide", but not in connection with a macrocyclic chelating agent.
  • the peptide of the invention can be labeled with salts of radionuclides in metal-free buffers at elevated temperature (Examples 2-4). The high labeling efficiency is that The peptide of the invention forms a stable chelate with In, 90 Y or 67/68 Ga under physiological conditions.
  • these chelates are in human serum or in the presence of a 10,000-fold excess of diethylenetriamine-pentaacetic acid (DTPA)
  • DTPA diethylenetriamine-pentaacetic acid
  • the peptide of the invention also forms stable chelates with rare earths ( 161 Tb, 153 Sm, etc.).
  • EP 0 714911A2 covers the use of DOTA octreotide in a form labeled with 90 Y or 161 Tb and with radionuclides which emit alpha, beta particles or Auger electrons.
  • radionuclides which capture an isomeric transition by making (such as 99m Tc)
  • electrons ie 67 Ga, In ⁇ n
  • positron proposed 68 Ga
  • the peptide of the invention can be based on
  • 1 1 1 1 ⁇ 7 / ⁇ R must be marked stable with In or Ga and is therefore not only suitable for therapy, but also for use as a radio diagnostic agent (both for SPECT and PET).
  • the octapeptide according to the invention has a broad somatostatin receptor recognition profile.
  • the radioactively labeled peptide with K values in the low nanomolar range binds to SSTR2, SSTR3, SSTR4 and also SSTR5 (Example 5).
  • the radiolabeled ligand also shows high affinity binding for PC3 and DU145 prostate cancer cells, PANC1 and HT29 adenocarcinoma cells, A431 epithelial cells, ZR75-1 and T47D breast cancer cells and for 518A2 melanoma cells.
  • the peptide also binds to a number of primary tumors such as breast cancer, melanoma, adenocarcinoma, lymphoma, liver cell tumor, thyroid tumor and various neuroendocrine tumors.
  • the most important somatostatin receptor expressed in the tumor appears to be SSTR3, which is a target R for the peptide of the invention (Example 6).
  • SSTR3 is a target R for the peptide of the invention (Example 6).
  • the experiments have shown that the binding behavior of the octapeptide on the one hand and that of the octapeptide associated with the macrocyclic chelating agent on the other hand is somewhat was different, which may be due to the different lipophilicity of the octapeptide in the unbound or bound state.
  • heavy metal atoms or metal ions with atomic numbers 20-32, 42-44, 45 and 57 to 83 can also be used for the medical imaging diagnosis.
  • Paramagnetic metals or metal ions with atomic numbers 21-29, 42, 44 or 57-71, in particular Gd 3+ , Mn 2+ or Dy 3+ can be used for a magnetic resonance display.
  • Alkali, alkaline earth or transition metals or metal ions, in particular Na + , K + , Ca 2+ , Fe 2 + / 3 + , Zn 2+ and Mn 2+ can also be used for pharmaceutical purposes.
  • the compound 1,4,7,10-tetraazacyclododecane-N, N ', N ", N"' tetraacetic acid (DOTA) was advantageously used as the chelating agent.
  • the conjugate resulting from Lanreotide and DOTA is relatively lipophilic and shows slower blood clearance and higher tumor accumulation than other somatostatin 14 analogues in humans. Due to the hydrophilicity of DOTA, the lipophilicity of the octapeptide used is reduced, which means that the tumors can be better displayed on the one hand, and on the other hand a lower absorption of this substance is achieved in the non-diseased organs, i.e. the non-target organs such as the spleen and kidney.
  • the lu In-labeled peptide of the invention was directly compared to ⁇ ⁇ In-DTPA- (D) Phe 1 octreotide.
  • intravenous application of the peptide of the invention (3 mCi, 6 nmol) compared to the lu In-DTPA- (D) Phe 1 -octreotide, there was a higher tumor uptake, a lower retention in the kidneys and a reduced uptake in the spleen (example 8th).
  • the diagnosis as a radionuclide ⁇ n In or Ga 67/68 be bound to the chelating agent, which has the advantage that this radionuclide Gamma radiation emitted, which is suitable for diagnosis, with less radiation exposure for the body.
  • the radionuclide 90 Y can be bound to the chelating agent, which is known to emit beta radiation which serves to destroy the tumor cells, the effect of the radionuclide essentially being restricted to the diseased cells due to the specific binding of the octapeptide ).
  • a "cocktail" of radioisotopes (such as 86 Y-labeled peptide and 90 Y-labeled peptide) or radionuclides (such as U1 In -labeled peptide and 90 Y-labeled peptide) for simultaneous diagnosis and radiotherapy can also be produced.
  • radioisotopes such as 86 Y-labeled peptide and 90 Y-labeled peptide
  • radionuclides such as U1 In -labeled peptide and 90 Y-labeled peptide
  • the radioactively labeled peptide can be used repeatedly to evaluate somatostatin receptor-positive tumor diseases or endocrinological diseases.
  • DOTA l, 4,7,10-tetraazacyclododecane-N, N ⁇ N ', N'-tetraacetic acid
  • BOC tert-butyloxycarbonyl 80 mg of DOTA, 74 mg of N-hydroxysuccinimide and 80 mg of [ ⁇ -Boc-Lys 5 ] lanreotide are dissolved in 15 mL H 2 O and 30 mL N, N-dimethylformamide. One hundred mg of NjN'-dicyclohexylcarbodiimide are added and the resulting solution is stirred at room temperature for 16 hours.
  • the product, [ ⁇ -DOTA- (D) - ßNal 1 , ⁇ -Boc-Lys 5 ] -lanreotide, is isolated and isolated on a silica gel 60 column using methylene chloride: methanol: 50% acetic acid (9: 1: 0.125 - »7: 3: 1) cleaned as a solvent.
  • the Boc-protected group is cleaved from the [ ⁇ -DOTA- (D) -ßNal 1 , ⁇ -Boc-Lys 5 ] - lanreotide product using 30 mL methylene chloride and 2 mL trifluoroacetic acid (30 minutes at room temperature).
  • the peptide of the invention is dissolved in 0.2 mol / L ammonium acetate buffer (metal-free, pH 7) and incubated with m InCl 3 (carrier-free, Me ++ ⁇ 0.1 ⁇ g / mCi, ⁇ 1 ⁇ g / mL) in 0.05 mol / L HC1 .
  • m InCl 3 carrier-free, Me ++ ⁇ 0.1 ⁇ g / mCi, ⁇ 1 ⁇ g / mL
  • a ratio of 0.5 mCi ⁇ ⁇ In: 1 nmol DOTA lanotide is produced and the reaction mixture is boiled at 100 ° C. for 30 minutes. An aliquot is checked for purity by means of thin layer chromatography. The radiochemical purity of the product is typically> 99%. If it is less, the product is cleaned with reversed phase LC or HPLC.
  • radioligand is taken up in a solution of 0.075 mol / L NaCl, 0.05 mol / 1 NHUOAc, 0.2 mol / L ascorbic acid and 0.1% human serum albumin and sterilized by filtration through a 0.2 ⁇ m membrane.
  • Example 3 Radiolabeling of the peptide with 90 Y
  • the labeled and unlabelled substance of the invention was examined in saturation studies and in competition studies in vitro for its binding to various tumor cells (primary tumors, immortal cells) and also to the somatostatin receptor subtypes SSTR1-SSTR5.
  • the subtype receptors were expressed on COS-7 cells using cDNA samples.
  • Comparative studies were carried out with other somatostatin receptor agonists.
  • 125 I-Tyr n -somatostatin-14 was also used as the radioligand.
  • the data below clearly show that there is a significant difference in binding to the SSTR3 as well as the SSTR4 between the peptide of the invention and the n ⁇ In-DTPA- (D) Phe 1 -ctreotide.
  • Receptor subtypes hSSTR1 to hSSTR ⁇ Receptor subtypes hSSTR1 to hSSTR ⁇ .
  • Gastric cancer colon and rectal cancer
  • Skin cancer Breast cancer
  • Pancreas thyroid tumors, lymphomas, lung cancer, various neuroendocrine tumors such as carcinoids, gastrinomas, pheochromocytomas; Prostate cancer, glandular cancer, and the daughter tumors of these tumors.
  • the biodistribution and dosimetry of ⁇ n In-labeled peptide of the invention was compared with the biodistribution and dosimetry of 1 I 1 In-DTPA (D) Phe 1 octreotide.
  • Approx. 3 mCi of one or the other substance was administered intravenously at intervals of approx. 6-8 weeks.
  • blood samples, urine samples and stool samples were examined for their radioactivity at different times.
  • the gamma radiation was recorded using a gamma camera, the measuring points being applied up to 144 hours after application.
  • the gamma camera images included whole-body images in anterior and posterior projection, as well as single-photon emission tomography (SPET) for precise tumor localization and size estimation.
  • SPET single-photon emission tomography
  • FIG. 1A From FIG. 1A it can be seen that the substance of the invention is excreted from the body somewhat more slowly than 111 In-DTPA- (D) Phe 1 octreotide.
  • the uptake of the peptide of the invention in the tumor is significantly higher in direct comparison (see FIG. 1B). It is also important that, compared to III In-DTPA- (D) Phe'-octreotide, the peptide of the invention a priori shows a significantly lower uptake in the spleen (FIG. IC) and kidneys (FIG. 1D). This biodistribution forms the basis for effective radiotherapy with the 90 Y-labeled peptide of the invention, since these organs are critical to radiation exposure. literature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une substance porteuse pour radionucléides servant au diagnostic et/ou à la radiothérapie de tumeurs positives ou de cellules cibles positives en ce qui concerne le récepteur de la somatostatine. Il s'agit d'un conjugué constitué d'agonistes de somatostatine 14 du lanréotide et d'un chélateur macrocyclique qui forme des chélates stables avec des radionucléides métalliques, dans des conditions physiologiques.
PCT/AT1998/000065 1997-03-14 1998-03-12 Ligands radiomarques du recepteur de la somatostatine pour le diagnostic et la theraphie WO1998041540A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002284581A CA2284581A1 (fr) 1997-03-14 1998-03-12 Ligands radiomarques du recepteur de la somatostatine pour le diagnostic et la theraphie
AU66021/98A AU6602198A (en) 1997-03-14 1998-03-12 Radiolabelled somatostatin receptor ligands for diagnosis and therapy
EP98907750A EP0975670A1 (fr) 1997-03-14 1998-03-12 Ligands radiomarques du recepteur de la somatostatine pour le diagnostic et la theraphie
JP53994098A JP2001515494A (ja) 1997-03-14 1998-03-12 診断及び治療のための放射能標識したソマトスタチン受容体リガンド

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0045197A AT405906B (de) 1997-03-14 1997-03-14 Radiomarkierte somatostatin rezeptor-liganden zur diagnose und therapie
ATA451/97 1997-03-14

Publications (1)

Publication Number Publication Date
WO1998041540A1 true WO1998041540A1 (fr) 1998-09-24

Family

ID=3490974

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT1998/000065 WO1998041540A1 (fr) 1997-03-14 1998-03-12 Ligands radiomarques du recepteur de la somatostatine pour le diagnostic et la theraphie

Country Status (6)

Country Link
EP (1) EP0975670A1 (fr)
JP (1) JP2001515494A (fr)
AT (1) AT405906B (fr)
AU (1) AU6602198A (fr)
CA (1) CA2284581A1 (fr)
WO (1) WO1998041540A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051095A2 (fr) * 2000-01-13 2001-07-19 Schering Aktiengesellschaft Derives paramagnetiques de type dota, agents pharmaceutiques les contenant, procedes permettant de les preparer et leur utilisation pour l'imagerie par resonance magnetique de necroses et de l'infarctus
US6358491B1 (en) 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
WO2003014157A2 (fr) * 2001-08-03 2003-02-20 Bracco Imaging S.P.A. Conjugues peptidiques, leurs derives a complexes metalliques et leur utilisation dans l'imagerie par resonance magnetique (irm)
EP1358890A1 (fr) * 2002-05-03 2003-11-05 BioSynthema, Inc Dérivés benzothiényle de la somatostatine, sélectifs pour certains récepteurs de la somatostatine
EP1416971A1 (fr) * 1999-08-16 2004-05-12 UAB Research Foundation Imagerie de transfert genique et ses utilisations
US7122622B2 (en) 2002-04-16 2006-10-17 Biosynthema Inc. Peptide compounds having improved binding affinity to somatostatin receptors
US10322191B2 (en) 2014-06-30 2019-06-18 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0588754A1 (fr) * 1992-09-15 1994-03-23 The Ohio State University Research Foundation Application de la cinétique de peptide/récepteur de cellule en utilisant des congénères de samotastatine radiomarquée en cours de la détection et différenciation de tissu néoplastique in situ et in vivo
EP0714911A2 (fr) * 1994-09-06 1996-06-05 Sandoz Ltd. analogues de somatostatine contenant des agents de chélation et leur compositions radio-marquées
WO1996039161A1 (fr) * 1995-06-05 1996-12-12 The Administrators Of The Tulane Educational Fund Analogues de la somatostatine contenant plusieurs de tyrosines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0588754A1 (fr) * 1992-09-15 1994-03-23 The Ohio State University Research Foundation Application de la cinétique de peptide/récepteur de cellule en utilisant des congénères de samotastatine radiomarquée en cours de la détection et différenciation de tissu néoplastique in situ et in vivo
EP0714911A2 (fr) * 1994-09-06 1996-06-05 Sandoz Ltd. analogues de somatostatine contenant des agents de chélation et leur compositions radio-marquées
WO1996039161A1 (fr) * 1995-06-05 1996-12-12 The Administrators Of The Tulane Educational Fund Analogues de la somatostatine contenant plusieurs de tyrosines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PLESS J ET AL: "(111IN-DTPA-D-PHE1)-OCTREOTIDE (SDZ 215-811) TO IMAGE SOMATOSTATIN RECEPTOR POSITIVE TUMORS", PEPTIDES: CHEMISTRY AND BIOLOGY, CAMBRIDGE, JUNE 16 - 21, 1991, no. SYMP. 12, 16 June 1991 (1991-06-16), SMITH J A;RIVIER J E, pages 106 - 108, XP000371753 *
WECKBERGER G. ET AL: "SOMATOSTATIN ANALOGS FOR DIAGNOSIS AND TREATMENT OF CANCER", PHARMACOLOGY AND THERAPEUTICS, vol. 60, no. 2, 1993, pages 245 - 264, XP002072560 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1416971A1 (fr) * 1999-08-16 2004-05-12 UAB Research Foundation Imagerie de transfert genique et ses utilisations
EP1416971A4 (fr) * 1999-08-16 2004-05-12 Uab Research Foundation Imagerie de transfert genique et ses utilisations
US6358491B1 (en) 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
WO2001051095A3 (fr) * 2000-01-13 2002-11-28 Schering Ag Derives paramagnetiques de type dota, agents pharmaceutiques les contenant, procedes permettant de les preparer et leur utilisation pour l'imagerie par resonance magnetique de necroses et de l'infarctus
WO2001051095A2 (fr) * 2000-01-13 2001-07-19 Schering Aktiengesellschaft Derives paramagnetiques de type dota, agents pharmaceutiques les contenant, procedes permettant de les preparer et leur utilisation pour l'imagerie par resonance magnetique de necroses et de l'infarctus
DE10002939C1 (de) * 2000-01-13 2001-09-20 Schering Ag Paramagnetische DOTA-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung für die Herstellung von pharmazeutischen Mitteln
WO2003014157A2 (fr) * 2001-08-03 2003-02-20 Bracco Imaging S.P.A. Conjugues peptidiques, leurs derives a complexes metalliques et leur utilisation dans l'imagerie par resonance magnetique (irm)
WO2003014157A3 (fr) * 2001-08-03 2003-11-13 Bracco Imaging Spa Conjugues peptidiques, leurs derives a complexes metalliques et leur utilisation dans l'imagerie par resonance magnetique (irm)
US7122622B2 (en) 2002-04-16 2006-10-17 Biosynthema Inc. Peptide compounds having improved binding affinity to somatostatin receptors
EP1358890A1 (fr) * 2002-05-03 2003-11-05 BioSynthema, Inc Dérivés benzothiényle de la somatostatine, sélectifs pour certains récepteurs de la somatostatine
WO2003092744A3 (fr) * 2002-05-03 2004-04-01 Biosynthema Inc Compose peptidique presentant une meilleure affinite de liaison avec les recepteurs de la somatostatine
US10322191B2 (en) 2014-06-30 2019-06-18 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
US10624967B2 (en) 2014-06-30 2020-04-21 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
US11458206B2 (en) 2014-06-30 2022-10-04 Tva (Abc), Llc Targeted conjugates and particles and formulations thereof

Also Published As

Publication number Publication date
CA2284581A1 (fr) 1998-09-24
ATA45197A (de) 1999-05-15
AU6602198A (en) 1998-10-12
EP0975670A1 (fr) 2000-02-02
JP2001515494A (ja) 2001-09-18
AT405906B (de) 1999-12-27

Similar Documents

Publication Publication Date Title
DE69535242T2 (de) Somatostatin bindende peptide-metallchelat konjugate
DE69819478T2 (de) Verfahren zum Nachweis und zur Lokalisierung maligner menschlicher Pankreastumore
de Jong et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA 0, d-Phe 1, Tyr 3] octreotide, a promising somatostatin analogue for radionuclide therapy
Kwekkeboom et al. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake
EP1784422B1 (fr) Invention concernant le glp-1 et l'exendine
Wester et al. PET-pharmacokinetics of 18F-octreotide: A comparison with 67Ga-DFO and 86Y-DTPA-octreotide
Kwekkeboom et al. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma
Breeman et al. The addition of DTPA to [177 Lu-DOTA 0, Tyr 3] octreotate prior to administration reduces rat skeleton uptake of radioactivity
EP0831938B1 (fr) Compositions de peptides radiomarques pour le ciblage specifique d'un site
AT405906B (de) Radiomarkierte somatostatin rezeptor-liganden zur diagnose und therapie
Pujatti et al. Development of a new bombesin analog radiolabeled with lutetium-177: in vivo evaluation of the biological properties in balb-c mice
US7122622B2 (en) Peptide compounds having improved binding affinity to somatostatin receptors
Pujatti et al. Radiolabeling of substance p with lutetium-177 and biodistribution study in rat pancreatic tumor xenografted nude mice
Stolz et al. Biological characterisation of [67Ga] or [68Ga] labelled DFO-octreotide (SDZ 216-927) for PET studies of somatostatin receptor positive tumors
US10471162B2 (en) Collagen targeted imaging probes
Breeman et al. Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0, Tyr3] octreotide solutions containing free 90Y3+
DE60014375T2 (de) Uebergangsmetallkomplexe der vii-nebengruppe mit multidentaten aminopolycarboxylat-liganden und ein kit zu deren herstellung
Traub-Weidinger et al. Preliminary experience with 68Ga-DOTA-lanreotide positron emission tomography
Lewis et al. Radiometal-labeled somatostatin analogs for applications in cancer imaging and therapy
DE60035787T2 (de) Neuropeptid-Y1-Rezeptor-bindende Verbindungen zur Behandlung und Diagnose von Krebserkrankungen
WO1995012613A1 (fr) Peptides capables de liaison avec les metaux et sans cysteine pour le diagnostic et le traitement, procedes pour leur preparation et compositions pharmaceutiques contenant ces composes
US20230293736A1 (en) [161Tb]-BASED RADIOPEPTIDES
US20240181094A1 (en) [161Tb]-BASED RADIOPEPTIDES
US20220080059A1 (en) RADIOLABELING AND FORMULATION FOR SCALE UP OF 64Cu-DOTATATE
US20050226813A1 (en) Labelled somatostatin analogs backbone cyclized through metal complexation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 1998 9025

Country of ref document: AT

Date of ref document: 19980924

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 19989025

Country of ref document: AT

ENP Entry into the national phase

Ref document number: 1998 539940

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2284581

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2284581

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1998907750

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998907750

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09380983

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1998907750

Country of ref document: EP